Although many DNA repair enzymes, such as PARP1, are considered as therapeutic targets [57], the advantage of selectively targeting DNA glycosylases in cancer and neurodegenerative diseases has emerged only recently. This evidence concerns the gene LIG4 and neurodegenerative disease.